Comparison of the efficacy and safety of bupropion versus aripiprazole augmentation in adults with treatment-resistant depression: a nationwide cohort study in South Korea
Vergleich der Wirksamkeit und Sicherheit von Bupropion versus Aripiprazol als Augmentation bei Erwachsenen mit behandlungsresistenter Depression: landesweite Kohortenstudie in Südkorea
European Psychiatry · 2025 · 68 (1)
DOI: 10.1192/j.eurpsy.2024.1815 ↗Auf einen Blick
Bei Erwachsenen mit behandlungsresistenter Depression war Bupropion mit einem geringeren Risiko für depressionbedingte Hospitalisierung und Bewegungsstörungen verbunden als Aripiprazol.
Fragestellung
Vergleich von Wirksamkeit und Sicherheit von Bupropion und Aripiprazol als Augmentationstherapie bei behandlungsresistenter Depression.
Methode
Populationbasierte retrospektive Kohortenstudie mit Daten aus einer landesweiten Claims-Datenbank in Südkorea; 1:1-Matching; as-treated-Primäranalyse und Intention-to-treat-Analyse; Subgruppenanalyse nach Alter.
Ergebnisse
5.619 Patient:innen. Bupropion vs. Aripiprazol: Hospitalisierung HR 0,51 (95 %-KI 0,29–0,86), Bewegungsstörungen HR 0,56 (95 %-KI 0,36–0,85), Krampfanfall HR 0,65 (95 %-KI 0,30–1,31). Bei ≥60-Jährigen keine signifikanten Unterschiede.
Schlussfolgerung der Autor:innen
Bupropion-Augmentation war mit einem signifikant geringeren Risiko für depressionbedingte Rehospitalisierung und Bewegungsstörungen verbunden.
Kernaussagen
- Hospitalisierung: HR 0,51 (95 %-KI 0,29–0,86) zugunsten von Bupropion
- Bewegungsstörungen: HR 0,56 (95 %-KI 0,36–0,85)
- Kein signifikanter Unterschied beim Krampfanfallrisiko
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Vergleichsstudie in der Zeitschrift European Psychiatry, online erschienen am 17.01.2025. Verfasst von Dong Yun Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea. Hauptthemen laut MEDLINE: Aripiprazole, Bupropion, Depressive Disorder, Treatment-Resistant, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education.
Themen: Depression
Abstract (Originalsprache)
Background
Treatment-resistant depression (TRD) affects 10–30% of patients with major depressive disorder, leading to increased comorbidities, higher mortality, and significant economic and social burdens. This study aimed to compare the efficacy and safety of bupropion and aripiprazole as augmentation therapies for TRD.
Methods
This population-based, retrospective cohort study included adults aged ≥18 years with a diagnosis of depressive disorder who met the criteria for TRD. Data were collected from a nationwide claims database in South Korea. Patients prescribed bupropion were matched 1:1 with those prescribed aripiprazole. Subgroup analyses were performed according to age. An as-treated analysis was performed as the primary analysis, and an intention-to-treat analysis was performed to identify different risk windows. The primary outcome was depression-related hospitalization, and the secondary outcomes were first-time diagnoses of movement disorder and seizure.
Results
A total of 5,619 patients (bupropion: n = 1,568; aripiprazole: n = 4,051) were included in this study. Bupropion was associated with lower risks of hospitalization (hazard ratio [HR]: 0.51; 95% confidence interval [CI] 0.29–0.86) and movement disorders (HR: 0.56; 95% CI 0.36–0.85) than aripiprazole. No significant difference in seizure risk (HR: 0.65; 95% CI 0.30–1.31) was observed between the two treatments. The subgroup analysis of participants aged ≥60 years revealed no significant differences in the three outcomes between the two medications.
Conclusions
Bupropion augmentation is associated with a significantly lower risk of depression-related re-hospitalization and movement disorders in patients with TRD. Therefore, bupropion augmentation can be a comprehensive treatment strategy for TRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.
- Bongdam Forest Mental Health Clinic, Hwaseong, Republic of Korea.
- Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.
- Jeju Research Institute of Pharmaceutical Science, College of Pharmacy, Jeju National University, Jeju, South Korea.
ORCID-Profile: Dong Yun Lee, Rae Woong Park, Soo Min Jeon
Förderung
- Ministry of Education
Zitieren
APA
Lee, D. Y., Park, R. W., & Jeon, S. M. (2025). Comparison of the efficacy and safety of bupropion versus aripiprazole augmentation in adults with treatment-resistant depression: a nationwide cohort study in South Korea. European Psychiatry, 68(1). https://doi.org/10.1192/j.eurpsy.2024.1815
Vancouver
Lee DY, Park RW, Jeon SM. Comparison of the efficacy and safety of bupropion versus aripiprazole augmentation in adults with treatment-resistant depression: a nationwide cohort study in South Korea. European Psychiatry. 2025;68(1). doi:10.1192/j.eurpsy.2024.1815
BibTeX
@article{Lee2025,
author = {Lee, Dong Yun and Park, Rae Woong and Jeon, Soo Min},
title = {Comparison of the efficacy and safety of bupropion versus aripiprazole augmentation in adults with treatment-resistant depression: a nationwide cohort study in South Korea},
journal = {European Psychiatry},
year = {2025},
volume = {68},
number = {1},
doi = {10.1192/j.eurpsy.2024.1815}
}
EUVIMED